We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Three Reasons to Hold BD (BDX) Stock in Your Portfolio Now
Read MoreHide Full Article
Becton, Dickinson and Company (BDX - Free Report) , popularly known as BD, is well-poised for growth in the coming quarters, courtesy of its solid product portfolio. The optimism led by a solid second-quarter fiscal 2024 performance and a few strategic deals are expected to contribute further. However, macroeconomic concerns and stiff competition persist.
Over the past year, this Zacks Rank #3 (Hold) stock has lost 12.3% compared with the 2% decline of the industry. The S&P 500 has witnessed 26.7% growth in the said time frame.
The renowned medical technology company has a market capitalization of $66.14 billion. It projects 8.8% growth for the next five years and expects to maintain its strong performance. BD’s earnings surpassed estimates in three of the trailing four quarters and broke even once, with the average surprise being 5.4%.
Image Source: Zacks Investment Research
Let’s delve deeper.
Strategic Deals: BD has inked a few strategic agreements for its products over the past few months, raising our optimism. Last month, the company announced a definitive agreement to acquire Edwards Lifesciences’ Critical Care product group (Critical Care).
In February, it announced a strategic partnership with Camtech Health to advance cervical cancer screening by offering the first-ever option for women in Singapore to self-collect a sample privately in their homes.
Product Portfolio: We are upbeat about BD’s slew of product launches in recent times. Last month, the company announced the commercial launch of a new single-cell research tool — BD Rhapsody ATAC-Seq Assay — to help scientists better understand how the molecular machinery within a cell functions and how it regulates changes in a cell that can lead to cancer and other diseases.
In May, BD received the FDA’s approval for the use of self-collected vaginal specimens for human papillomavirus testing when cervical specimens cannot otherwise be obtained.
Strong Q2 Results: BD’s solid second-quarter fiscal 2024 results buoy our optimism. The company registered solid top-line results, along with improvements in organic revenues and bottom-line performances. Robust performances by all segments and both geographic regions were also recorded. Strength in most of BD’s segment’s business units during the reported quarter was also seen.
Downsides
Macroeconomic Concerns: Global economic challenges, including rising inflation and volatile capital markets, among others, pose risks to the demand and pricing of BD’s products and services. These conditions can disrupt its supply chain, impact production, and increase its borrowing costs, affecting its business.
Stiff Competition: BD operates in an increasingly complex and challenging medical technology marketplace. Although technological advances and scientific discoveries have accelerated the pace of change in medical technology, the regulatory environment of medical products is becoming more complex and vigorous. Acquisitions and collaborations by and among companies seeking a competitive advantage also affect the competitive environment.
Estimate Trend
BD is witnessing a positive estimate revision trend for fiscal 2024. In the past 90 days, the Zacks Consensus Estimate for its earnings has moved 0.8% north to $13.04.
The Zacks Consensus Estimate for the company’s third-quarter fiscal 2024 revenues is pegged at $5.07 billion, indicating a 3.9% improvement from the year-ago quarter’s reported number.
Key Picks
Some better-ranked stocks in the broader medical space are DaVita Inc. (DVA - Free Report) , Stryker Corporation (SYK - Free Report) and Ecolab Inc. (ECL - Free Report) .
DaVita, carrying a Zacks Rank #2 (Buy) at present, has an estimated long-term growth rate of 13.6%. DVA’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 29.4%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
DaVita’s shares have gained 34.2% compared with the industry’s 12.7% rise in the past year.
Stryker, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 10.6%. SYK’s earnings surpassed estimates in each of the trailing four quarters, with the average being 4.9%.
Stryker has gained 12.2% against the industry’s 2.4% decline in the past year.
Ecolab, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 14.3%. ECL’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 1.3%.
Ecolab’s shares have rallied 29% against the industry’s 12.8% decline in the past year.
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Three Reasons to Hold BD (BDX) Stock in Your Portfolio Now
Becton, Dickinson and Company (BDX - Free Report) , popularly known as BD, is well-poised for growth in the coming quarters, courtesy of its solid product portfolio. The optimism led by a solid second-quarter fiscal 2024 performance and a few strategic deals are expected to contribute further. However, macroeconomic concerns and stiff competition persist.
Over the past year, this Zacks Rank #3 (Hold) stock has lost 12.3% compared with the 2% decline of the industry. The S&P 500 has witnessed 26.7% growth in the said time frame.
The renowned medical technology company has a market capitalization of $66.14 billion. It projects 8.8% growth for the next five years and expects to maintain its strong performance. BD’s earnings surpassed estimates in three of the trailing four quarters and broke even once, with the average surprise being 5.4%.
Image Source: Zacks Investment Research
Let’s delve deeper.
Strategic Deals: BD has inked a few strategic agreements for its products over the past few months, raising our optimism. Last month, the company announced a definitive agreement to acquire Edwards Lifesciences’ Critical Care product group (Critical Care).
In February, it announced a strategic partnership with Camtech Health to advance cervical cancer screening by offering the first-ever option for women in Singapore to self-collect a sample privately in their homes.
Product Portfolio: We are upbeat about BD’s slew of product launches in recent times. Last month, the company announced the commercial launch of a new single-cell research tool — BD Rhapsody ATAC-Seq Assay — to help scientists better understand how the molecular machinery within a cell functions and how it regulates changes in a cell that can lead to cancer and other diseases.
In May, BD received the FDA’s approval for the use of self-collected vaginal specimens for human papillomavirus testing when cervical specimens cannot otherwise be obtained.
Strong Q2 Results: BD’s solid second-quarter fiscal 2024 results buoy our optimism. The company registered solid top-line results, along with improvements in organic revenues and bottom-line performances. Robust performances by all segments and both geographic regions were also recorded. Strength in most of BD’s segment’s business units during the reported quarter was also seen.
Downsides
Macroeconomic Concerns: Global economic challenges, including rising inflation and volatile capital markets, among others, pose risks to the demand and pricing of BD’s products and services. These conditions can disrupt its supply chain, impact production, and increase its borrowing costs, affecting its business.
Stiff Competition: BD operates in an increasingly complex and challenging medical technology marketplace. Although technological advances and scientific discoveries have accelerated the pace of change in medical technology, the regulatory environment of medical products is becoming more complex and vigorous. Acquisitions and collaborations by and among companies seeking a competitive advantage also affect the competitive environment.
Estimate Trend
BD is witnessing a positive estimate revision trend for fiscal 2024. In the past 90 days, the Zacks Consensus Estimate for its earnings has moved 0.8% north to $13.04.
The Zacks Consensus Estimate for the company’s third-quarter fiscal 2024 revenues is pegged at $5.07 billion, indicating a 3.9% improvement from the year-ago quarter’s reported number.
Key Picks
Some better-ranked stocks in the broader medical space are DaVita Inc. (DVA - Free Report) , Stryker Corporation (SYK - Free Report) and Ecolab Inc. (ECL - Free Report) .
DaVita, carrying a Zacks Rank #2 (Buy) at present, has an estimated long-term growth rate of 13.6%. DVA’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 29.4%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
DaVita’s shares have gained 34.2% compared with the industry’s 12.7% rise in the past year.
Stryker, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 10.6%. SYK’s earnings surpassed estimates in each of the trailing four quarters, with the average being 4.9%.
Stryker has gained 12.2% against the industry’s 2.4% decline in the past year.
Ecolab, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 14.3%. ECL’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 1.3%.
Ecolab’s shares have rallied 29% against the industry’s 12.8% decline in the past year.